Journal of Advanced Zoology

ISSN: 0253-7214
*Volume **44** Issue **04 Year 2023** Page **357:373***

Phytonano particles for the Treatment of Type 2 Diabetes Mellitus: A Review

Nagineni Sudarshan Rao[1,2], P. Balaji[3*]

[1]Research Scholar, Department of Pharmaceutical Sciences, Vels Schools of Pharmaceutical Sciences, VISTAS Chennai, Tamil Nadu, India naginenisudarshanrao@gmail.com
[2]Assistant Professor, Department of Pharmaceutics, Shri Vishnu College of Pharmacy, Bhimavaram, Andhra Pradesh, India naginenisudarshanrao@gmail.com
[3]Professor, Department of Pharmaceutical Sciences, Vels Schools of Pharmaceutical Sciences, VISTAS Chennai, Tamil Nadu, India pharmacology.balaji@gmail.com.

**Corresponding author's E-mail: pharmacology.balaji@gmail.com.*

Article History

Received: 06 June 2023
Revised: 05 Sept 2023
Accepted: 16 Nov 2023

Abstract

A metabolic syndrome that poses a life-threatening risk is diabetes mellitus. The prevalence of diabetes has increased dramatically during recent decades. Although several therapeutic strategies have been tried, the danger and occurrence continue unabated. Several tiny compounds produced from plants have been suggested to combat type 2diabetes and its related vascular problems by a variety of therapeutic objectives. Additionally, these phytochemicals' enhancing biocompatibility increases the desire to use them in therapeutic negotiations. Poor pharmacokinetics, however, because the clinical relevance of these phytochemicals is mostly constrained by their biological properties as drugs for treatment. Several pharmaceutical initiatives have been made to improve adherence and treatment effectiveness. The use of nanotechnology in this context has been demonstrated to be the most effective strategy for increasing compliance and clinical effectiveness. Due to the following, hyperglycemia either insufficient or resistant insulin secretion. The number of instances of diabetes mellitus is rising quickly in India, where it already affects more than 40 million people, or about 9% of the population.20% of the world's diabetes population. The usage of oral medications helped the type2DM patients receives treatment. Agents that lower blood sugar and insulin. But none of these treatments are particularly effective, and have negative impacts been mentioned. The researchers have relocated to a different location to help them other complementary medical practices. Folk medicines, often known as "traditional medicines," include extracts from various phytoconstituents. The management and control of diabetes mellitus has been greatly assisted by the use of medicinal herbs. This article gives a careful and current outline of the utilization of phytochemical Nano formulations in the treatment of diabetes and its ramifications. The impacts of nanosizing on pharmacokinetic, biopharmaceutical and remedial profiles of plant-determined little particles, for example, curcumin, resveratrol, naringenin, quercetin, apigenin, baicalin, luteolin, rosmarinic corrosive, berberine, gymnemic corrosive, emodin, scutellarin, catechins, thymoquinone, ferulic corrosive, stevioside, and others have been talked about exhaustively in this review.

Keywords: *Diabetes type2, bioavailability, medication delivery, nanotechnology, natural products, and phytochemicals.*

1. Introduction

According to projections by the International Diabetes Federation, the number of persons with diabetes will increase from 285 million in 2010, making up 6.4% of the adult population worldwide by 2030, to 438 million. India is now recognized as the world's diabetic epicenter. At this time, 40.9 million. People in India will still have DM in 2030, according to estimates might reach 79.44 million [1]. Diabetic nephropathy is a syndrome that is distinguished by hyperglycemia, decreased the amount of insulin produced by an increase in the amount of pancreatic islet cells Glucose levels [2]. A disease called

diabetes insipidus exists a condition that is characterized by the excretion of a lot of urine, which cannot be decreased by reducing fluid intake; the cause of this is antidiuretic hormone. There are numerous medications available today to treat type2 diabetes by improving insulin sensitivity, increasing insulin production, and reducing glucose intake blood level is at. The negative impact of drug rehabilitation is not always sufficient to maintain a typical level of glucose levels [5]. Recent advances in nanoscience and nanotechnology have expanded the range of possible applications. Nanotechnology offers a wide range of uses, especially in the medical and health sciences. Nanosized formulations present an unparalleled opportunity in the realm of medical science. Improved clinical effectiveness of medication delivery technologies above traditional formulations medicinal drugs by enhancing their pharmacokinetic profiles and biopharmaceutical characteristics, and target particularity [1]. the creation of drug nanoparticles with nanocarriers, like metallic nanoparticles, nanomicelles, dendrimers, liposomes, niosomes, and polymeric nanoparticles. Nanofabricated devices, lipid carriers with nanostructures, and stimuli-responsive nanoparticles have all been shown to be far more effective than traditional medication delivery methods, drug release, biodistribution, bioavailability, and stability [1].

Many scientists are interested in developing novel formulations against various diseases, including various types of cancer, inflammatory disorders, cardiovascular diseases, infectious diseases, etc. because of the increased success of nanostructured drug delivery systems [2]. Additionally, it was discovered that nano formulations were effective at treating common metabolic syndrome conditions like diabetes mellitus and delivering oral hypoglycemic medications and insulin. Hypoglycemic agent nanoparticles built on nanocarrier's aid in the functionalization of antidiabetic drugs by enhancing drug penetration to the intended target, extending the hypoglycemic impact, and reducing the possibility of adverse reactions. Multiple studies over time produced numerous target-specific small molecules from Plant phenolics are among the natural resources that are useful against diabetes [3]. The intriguing antidiabetic activity of several of these has been discovered in vitro [3]. However, there is a discrepancy between the in vitro findings and in vivo consequences, which lessens their clinical applicability [4]. poorly soluble in water It has been discovered that quick metabolism, low bioavailability, and high P-glycoprotein (P-gp) efflux be responsible for their ineffectiveness poor vivo [3, 5]. To remedy the pharmaceutical industry's ineptitude utilizing the anti-diabetic properties of these substances and other pharmacological techniques such Micronization, lipid-based emulsion systems, solid dispersions, hydrotrophy, etc., have been put up by several scientists over time [6].However, it has been discovered that nanocarrier-assembled nanosized drug delivery offers considerable advantages over alternative dosage forms for delivering naturally occurring antidiabetic drugs with subpar pharmacological properties [1].

To work on restorative viability by diminishing dosing recurrence, expanding bioavailability, accomplishing supported discharge properties, advancing selectivity, and lessening other troublesome biopharmaceutical ascribes, the nanodrug conveyance framework is presently getting increasingly more consideration in plan improvement research [6]. The unique qualities of antidiabetic drug Nano formulations derived from natural sources were highlighted in this review.

Causes and complications of type 2 diabetes:

Diabetes type 2 is a chronic condition. It is characterized by elevated blood sugar levels. Type 2 diabetes is also known as adult-onset diabetes and type 2 diabetes mellitus. This is due to the fact that it used to begin virtually always in middle age or later. However, this illness is becoming more prevalent in kids and teenagers. Type 2 diabetes is actually a different condition than type 1 diabetes and is far more prevalent. However, it also has high blood sugar levels and problems like type 1 diabetes. Food is broken down into its simple elements during digestion. Simple sugars, primarily glucose, are formed when carbohydrates are broken down. For the body's cells, glucose is a vital source of energy. Glucose must go from the blood and enter the cells in order to provide them energy. The blood-borne insulin instructs the cells to take up glucose. The pancreas produces the hormone insulin. An organ in the belly is the pancreas. The pancreas generates more insulin when blood glucose levels increase (for as following a meal).



Figure1: Type 2 Diabetes risk factors

When your body's cells reject insulin's intended result of pushing blood glucose into the cells' interiors, type 2 diabetes develops. The blood-borne insulin instructs the cells to take up glucose. The pancreas produces the hormone insulin. An organ in the belly is the pancreas. The pancreas generates more insulin when blood glucose levels increase (for as following a meal). When your body's cells reject insulin's intended result of pushing blood glucose into the cells' interiors, type 2 diabetes develops. Generally speaking, type 2 diabetes has two issues. Insulin, a chemical that controls how rapidly sugar enters cells, isn't delivered by the pancreas in adequate sums. Moreover, cells retain less sugar and have a powerless insulin reaction. Despite the fact that type 1 and type 2 diabetes can begin in youth and adulthood, separately, type 2 diabetes used to be delegated grown-up beginning diabetes. More seasoned people are bound to have type 2. In any case, more youthful people are creating type 2 diabetes because of the ascent in the quantity of corpulent youngsters. The blood-borne insulin instructs the cells to take up glucose. The pancreas produces the hormone insulin. An organ in the belly is the pancreas. The pancreas generates more insulin when blood glucose levels increase (for as following a meal). When your body's cells reject insulin's intended result of pushing blood glucose into the cells' interiors, type 2 diabetes develops. When an individual has insulin resistance, the pancreas "sees" an increase in blood glucose levels. In response, the pancreas produces more insulin to keep blood sugar levels normal. The body's insulin resistance worsens over time. The pancreas produces increasingly more insulin in response. The pancreas eventually becomes "exhausted". It is unable to meet the demand for ever-increasing amounts of insulin. It passes waste. Blood glucose levels consequently start to increase. Diabetes type 2 runs in families. Diabetes risk is significantly increased by obesity.





Figure2: Type 2 DiabetesFigure3: Type 2 Diabetes Insulin Resistance

Symptoms:

The blood-borne insulin instructs the cells to take up glucose. The pancreas creates the chemical insulin. An organ in the stomach is the pancreas. The pancreas creates more insulin when blood glucose levels increment (for as following a dinner). When your body's cells reject insulin's intended result of pushing blood glucose into the cells' interiors, type 2 diabetes develops. High blood glucose levels are associated with the symptoms of diabetes. They consist of: extreme thirst, hunger, and urination Loss of weight increased sensitivity to infections, particularly yeast or fungal infections Hyperosmolar syndrome, a harmful consequence brought on by dangerously high blood sugar levels, is another risk factor. This type of dehydration poses a life-threatening risk. Hyperosmolar syndrome may occasionally be a person's initial indication that they have type 2 diabetes. It results in foggy thinking, weakness, nausea, seizures, and even coma and coma. Symptoms of type 2 diabetes treatment are also possible. Hypoglycemia, often known as low blood sugar, can result from taking too many glucose-lowering medications in relation to nutritional intake. Hypoglycemia symptoms include: The blood-borne insulin instructs the cells to take up glucose. The pancreas produces the hormone insulin. An organ in the belly

is the pancreas. The pancreas generates more insulin when blood glucose levels increase (for as following a meal). When your body's cells reject insulin's intended result of pushing blood glucose into the cells' interiors, type 2 diabetes develops.

Sweating

Trembling

Dizziness

Confusion

If hypoglycemia is not identified and untreated, seizures and loss of consciousness may occur.

Small Molecules Derived from Plants as Anti-Diabetic Agents

Significant antidiabetic effects have been reported for many secondary metabolites produced from plants. It has been found that plant optional metabolites have antidiabetic impacts through different components, including restraint of glucose retention, reclamation of the practical mass of cells, improvement of insulin articulation, inversion of insulin opposition, advancement of glucose use, and guideline of sugar and lipid digestion. Regular plant-inferred particles and concentrates, including berberine, ginsenosides, curcumin, stevioside, gingerols, capsaicin, catechins, basic phenolic compounds, anthocyanins, resveratrol, genistein, and hesperidin, are utilized to treat diabetes and have been found to have a wide range of restorative impacts. The significance of medicinal plants and their active ingredients for anti-diabetic medications are discussed in this review. The current study also stressed the significance of controlling diabetes, reducing its complications, and using anti-diabetic medications. The specific mechanisms by which these extracts and compounds carry out their functions are also discussed. However, in order to be utilized as contemporary commercial medicines, anti-diabetic pharmaceuticals derived from plants must undergo scientific validation through animal and clinical research.



Figure4: depicts the several therapeutic targets for plant secondary metabolites in the treatment of diabetes. Downstream cellular events are shown by orange arrows, upregulation by upward arrows, downregulation by upward arrows, activation by green arrows, and inhibition by red lines. Protein kinase A is known as Akt, while AMPK is 50 AMP-activated protein kinase Forkhead box protein O, G6: FoxOIL stands for interleukin, GLUT stands for glucose transporter, and Pase Phosphoenolpyruvate Carboxykinase, or PEPCK, is an insulin receptor substrate-1. PGC-1, PI3K, and TNF-a are acronyms for peroxisome proliferator-activated receptor-coactivator-1, phosphoinositide 3-kinase, and tumor necrosis factor-a, respectively.

A number of phytochemicals, including -amylase, -glucosidase, and -glucosidase, have been shown to prevent postprandial hyperglycemia by interfering with the digestion of carbohydrates and delaying the absorption of glucose [18]. Intestinal enzymes that break down carbohydrates can be inhibited by resveratrol, myricitrin, baicalin, apigenin, quercetin, naringenin, curcumin, luteolin scutellarin, gallic acid, rosmarinic acid, and certain anthocyanins [18–24]. Reduced insulin secretion can lead to prolonged hyperglycemia as a result of the progressive functional loss of beta cells in the diabetic environment brought on by high lipids, high glucose, inflammatory mediators produced by adipose tissue, and endoplasmic reticulum stress. It has been suggested that curcumin, gymnemic acids, silymarin, quercetin, resveratrol, and berberine can contribute to the potential therapeutic approach in diabetes by restoring functional mass of pancreatic cells through various targeting [25]. By inhibiting phosphodiesterases in cells, curcumin and resveratrol can reduce pathogenic signaling events and enhance cell function [26]. By encouraging sirtuin 1 (SIRT1) activation, which then encourages pancreatic and duodenal homeobox 1 (PDX1)-triggered insulin expression and discourages forkhead box O1 (FoxO1)-governed transcriptional activity, resveratrol can restore cell function [27]. Through the inhibition of dipeptidyl peptidase-IV (DPP-4), manniferin can promote cell function [28]. By enlisting glucose transporter type (GLUT)2 signaling, gymnemic acid has been proposed to defend cells against oxidative damage and increase glucose-induced insulin secretion [29]. Asian acid may by supporting the expressions of protein kinase B (Akt) and B-cell lymphoma-extralarge (Bcl-xL), the cell population can be preserved [32]. Flavonoids guarantee cell survival in the presence of high levels of lipids, glucose, and via blocking nuclear factor, pro-inflammatory cytokines Activated B kappa-light-chain enhancer cells' (NF-B) activation, support for PI3K/Akt signaling, and inhibition of nitric oxide production reducing oxidative stress and increasing oxide generation [33]. Flavonoids can also revive the secretory function of cells via protein kinase C, protein kinase A, and phospholipase C (PLC), control of cyclic adenosine monophosphate (cAMP) [33]. Function of can be recovered by naringenin B-cell lymphoma 2 (Bcl2), GLUT2, PDX1, Akt, insulin receptor substrate (IRS), and the 70/90 genes for heat shock protein (Hsp) [34]. Furthermore, it can stop cell loss by suppressing genes that promote apoptosis, like Bcl-2-associated X.Utilization of glucose is principally hampered by insulin resistance in type 2 diabetes [37]. returning to an effective treatment for insulin resistance is insulin signaling [37]. The essential elements of insulin include insulin receptor (IR), insulin receptor substrate (IRS)-1, PI3K, Akt, and GLUT4. Skeletal muscle signaling [9, 15]. IRS1 is phosphorylated at Tyr 895, activating PI3K, which then encourages Akt phosphorylation at Ser 473 and Thr308, which causes GLUT4 translocation. [9, 15] enters the membrane. The uptake and use of glucose can be aided by GLUT4 translocation. Cellular energy homeostasis in this process is regulated by AMP-activated protein kinase (AMPK) [9,15]. In addition, by blocking the phosphorylation of Akt, phosphorylated Akt can impede FoxO1 activation. FoxO1 inhibits the expression of genes involved in gluconeogenesis in the liver, including phosphoenolpyruvate glucose-6-phosphatase (G6Pase) and PEPCK (PEPCK) [38]. Subtypes of the peroxisome proliferator-activated receptor (PPAR) are thought to be important. metabolic controllers. While PPAR- encourages glucose and lipid uptake, glucose oxidation, and insulin responsiveness, PPAR- and PPAR-/ are implicated in fatty acid uptake and fatty acid oxidation [51]. According to reports, a number of phytochemicals activate PPARs, making them crucial players in dealing with diabetes management. Scutellarin [55], glycyrrhizin [54], berberine [53], curcumin [52], andwere discovered to stimulate PPAR- in adipose tissue, hence stimulating glucose and lipid metabolism;While naringenin (56), myricetin (57), quercetin (58), mangiferin (59), ferulic acid (60), and bixin (61),Asiatic acid [64], glycyrrhizin [54], -eleostearic acid [63], and silymarin [62] can promote hepaticPPAR-activation through supporting lipid metabolism. Gymnemic acid was discovered to support fatty acids. Furthermore, the therapeutic efficacy of plant-derived small molecules against diabetes-related vascular issues, including nephropathy, retinopathy, cardiomyopathy, neuropathy, adipose tissue dysfunctions, hepatic problem, and other vascular disorders, can be brought on by a number of mechanisms. Specifically, by inducing free radicals, hyperglycemia can cause oxidative stress,radical generation and compromising the body's natural redox defense mechanism [9,12,14,15,72]. Oxidative stress promotes apoptosis, fibrosis, autophagic dysfunction, and inflammation at the same timesupporting transforming growth factor 1, mitogen-activated protein kinase (MAPK), PKC, NF-B, and (Smad) 2, 3, and 4/-

smooth muscle actin/(TGF-1)/mothers against decapentaplegic homologcollagen signaling and (-SMA) [12–14]. Conversely, antidiabetic substances generated from plants can reduce diabeticthrough controlling blood sugar, activating antioxidants, and preventing harmfulsignal transductions connected to apoptosis, fibrosis, and inflammation (Figure 4). [73] Curcumin,Quercetin (75), apigenin (76, 77), myricitrin (78, 79), resveratrol (74), naringenin (34), Despite the fact that the aforementioned plant-derived compounds showed great promise for reducing diabetes and associated problems in preclinical testing, but limited systemic availability due to unfavorable molecular size, poor water solubility, poor lipophilicity, quick metabolism, and lower penetrability and their clinical effectiveness as diabetic treatment drugs is significantly constrained by strong P-gp efflux control [3, 11]. Table 1 illustrates the ineffectiveness of plant-derived diabetes medications molecules. As a result, formulation makers actively engage in research to determine their optimum therapeutic output by creating original formulas. In this case, a formulation based on nanotechnology. Designing is becoming more popular as a means of improving and eradicating pharmacological ineptitude.Small-molecule medicines' bioavailability can be impacted by hyperglycemia by way of changes in absorption, distribution, biotransformation, and excretion. The bioavailability of drugs and dietary polyphenols varies depending on daily dose, component complexity, and food interaction. Food polyphenols are inefficiently absorbed, processed, and excreted. Only 5 to 10% of polyphenols are really absorbed, and the majority of those that are digested end up in the colon (more than 90%). Contrarily, clinical medications are often well absorbed and delivered to the tissues they are meant to treat. The metabolism of glucose, proteins, and lipids is impacted by hyperglycemia. The biotransformation of phytochemicals typically involves the same regulatory systems that regulate these metabolic pathways. Therefore, hyperglycemia affects the bioavailability of dietary polyphenols. Area under the curve and Cmax.



Figure 5 shows how plant secondary metabolites generally protect against diabetes problems. Upward arrows denote up regulation, downward arrows denote down regulation, and red lines denote inhibition. Orange arrows denote downstream cellular activities. Advanced glycation end products, or AGEs a cell surface death receptor known as FAS. IB stands for inhibitor of nuclear factor of kappa light polypeptide gene enhancer in B cells. c-Jun N-terminal kinases, or JNK Mitogen-activated protein kinase, or MAPK, Nuclear factor kappa-light-chain-enhancer of activated B cells is referred to as NF-B. Reactive oxygen species (ROS) mothers opposed to decapentaplegic homolog Transforming growth factor-1 (TGF-1) and tumor necrosis factor receptor (TNFR).

Phytonano formulations in Type2 Diabetes Treatment:

Approaches based on nanotechnology provide better therapeutic control of diabetes mellitus with reduced risk of acute and long-term consequences [1]. For the treatment of diabetic mellitus, a wide range of nanoformulation with different architectural styles have been created [186]. Formulations based on nanocarriers guarantee effective drug delivery to the target site with the pattern of release that is intended [1,18]. Additionally, nano-formulations permit the delivery of medications via different routes [16, 17]. When nanocarriers are created with the right ligands, they become more focused and can improve the stability and systemic availability of medications. The creation of nanocarriers also cut back on the drug's dosage and administration schedule. Manufactured nanoformulation are the last can lower the chance of toxic symptoms [1,14]. Therefore, appropriately created nanoformulation of hypoglycemic drugs may provide better diabetes therapeutic control.

Curcumin

One of the most promising methods to increase the solubility, stability, bioavailability, and therapeutic effectiveness of curcumin is the creation of nanoformulations diabetic medication. A self-nanophospholipid that contains curcumin was created by Allam and his coworkers.A phosphatidyl-choline derived from soybean lecithin called Phosal®53 MCT can be an effective lipophilic chemical solvent [19]. In comparison to standard formulations, curcumin-self-nanophospholipid dispersions were found to increase oral bioavailability in rats [45]. In diabetic rats, the expression of insulin and insulin receptor (IR) mRNAs was reported to be dramatically increased by curcumin nanoparticles produced using a modified emulsion-diffusion-evaporation approach, which also reduced fasting blood glucose and glycosylated hemoglobin levels [46]. According to claims made in diabetes therapy, curcumin-ZnO (10 mg/kg, for 21 days) nanoparticles are more effective than curcumin nanoparticles (50 mg/kg, for 21 days) in lowering blood sugar, improving serum insulin, and activating the GLUT2 and glucokinase genes in the pancreas and liver of type 2 diabetic rats [19].Multi-polymeric nanocarriers encapsulating curcumin had greater pharmacological results in the care of diabetic cardiomyopathy involves the cross-regulation of Ca2+/calmodulin, calcium-sensing receptor gene, and endogenous cystathionine -lyase/H2S as opposed to traditional curcumin formulations [38] in rats. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles encapsulated with curcumin were discovered to be efficient at improving and increasing the relative oral bioavailability of curcumin (5.6-fold compared to natural curcumin) curcumin's biological half-life by making it more water soluble and causing intestinal drug release juice, improving permeability, preventing P-gp efflux, and prolonging intestinal stay void [41]. Curcumin's ability to self-nanoemulsify has been shown to increase plasma affinity can increase curcumin's oral absorption [44]. the formulation of self-nanoemulsified curcumin revealed superior anti-diabetic efficacy to native curcumin in an experimental setting correcting functional, behavioral, and biochemical impairments in neuropathy.

Resveratrol

It has been suggested that resveratrol's poor pharmacokinetic and biopharmaceutical properties contribute to dose escalation and frequent administration to achieve desired therapeutic effects [24]. various tactics, like chemical alterations, the addition of bioenhancers, the creation of resveratrol prodrugs, and medicinal incompetence can be addressed by the creation of innovative medicinal formulations [24] of resveratrol. However, resveratrol has been nanoencapsulated in lipid nanocarriers, nanoemulsions, and there has been evidence that micelles, polymeric particles, solid dispersions, and nanocrystals are superior to alternative methods to obtain higher stability, increased bioavailability, and specific enhanced patient compliance, improved patient targeting, and improved therapeutic efficacy [24,16]. Resveratrol-loaded Polyallylamine hydrochloride and dextran are divided into 5.5 bilayers in the layer-by-layer nanoformulation. It was discovered that sulfate and resveratrol nanocores improved the stability and systemic availability.Resveratrol-loaded with notable improvements in encapsulation effectiveness, drug loading capacity, solubility, absorption, bioavailability, and sustained release, PLGA nanoparticles demonstrated excellent and reliable delivery resveratrol release to reduce non-

alcoholic fatty liver disease, which is closely related to diabetes type 2 [23]. Additionally, it has been discovered that galactosylated PLGA may serve as a nanocarrier for the Reservatrol is delivered orally for increased absorption and therapeutic effectiveness [24]. Oral good inhibitory results on the were seen following treatment with resveratrol-assembled gold nanoparticles activation of monocyte chemotactic protein-1 (MCP-1), vascular endothelial growth factor (VEGF)-1, and extracellular signal-regulated kinase (ERK) 1/2, NF-B, intercellular adhesion molecule-1 (ICAM-1), TNF, IL-6, and IL-1 genes have been found in diabetic rat retinas [25]. The nanoformulations may also result inthe activation of PEDF mRNA, or retinal pigment epithelium-derived factor.

Naringenin

To optimize the pharmacokinetic and metabolic properties of drugs, several pharmacological techniques have been implemented, including formulation with solubility enhancers, P-gp inhibitors, and metabolic inhibitors. Clinical relevance is achieved via naringenin's biopharmaceutical characteristics [68]. However, formulation design based on nanotechnology has become a more promising approach than others to reduce pharmacological weaknesses and improve naringenin's medicinal effectiveness. Using PVP (polyvinylpyrrolidone) K-90 as a stabilizer, naringenin nanoemulsification was developed. has been discovered to enhance the oral bioavailability, solubility, and gastrointestinal absorption of native naringenin [77] above naringenin. Naringenin delivery system that is self-nanoemulsified. Naringenin was discovered to enhance medication release, absorption, and oral bioavailability when compared to free suspension of drugs [21].

Quercetin

Quercetin nanofabrication has provided significant prospects to enhance oral bioavailability, target specificity, therapeutic efficacy, and adherence. Quercetin nanoparticles on PLGA were found to more than five times improve quercetin's oral bioavailability compared to free quercetin [79]. The quercetin in this quercetin nanoformulation was released over a period of up to six days [80].

Decreased therapeutic dose and improved therapeutic compliance result from the formulation. In diabetic mice, oxidative stress (liver, kidney, and pancreas) and alterations in glucose-metabolizing enzymes were reciprocated by hyperglycemia, which was effectively treated by quercetin nanorods with better medicinal properties [82]. It has been demonstrated that nanorods improve quercetin biodistribution and cellular uptake at the target areas, which increases the effectiveness of diabetic control [83]. PEG-block-[poly-(ethylenediaminel-glutamate)-graft-poly-(benzyloxy-carbonyl-l-lysine)]-loaded with quercetin by increasing the serum concentration of quercetin in rats, nanocarrier significantly enhanced the therapeutic potential of quercetin compared to free quercetin in the management of diabetes and associated nephropathy [84]. When compared to natural quercetin, quercetin-loaded solid lipid nanoparticles showed increased oral bioavailability and absorption [73]. When quercetin-succinylated chitosan-alginate core-shell-corona shaped nanoparticles were administered orally, they significantly enhanced the oral hypoglycemic impact of quercetin in diabetic rats.

Apigenin

A number of nanoformulations have been suggested to boost the therapeutic effectiveness of apigenin, which have simultaneously increased bioavailability and ensured precise targeting the dissolving rate of apigenin-pluronic F127 nanoparticles was reported to be improved by microwave synthesis increased oral absorption of apigenin, increasing its oral bioavailability by more than three times compared to using the commercial pill [12] a system of nanomixed micelles with apigenin that also contains Soluplus same, pluronic F127 polymers are asserted to increase oral bioavailability (> four-fold), accomplish apigenin is more readily absorbed through the gastrointestinal tract when it is released gradually rats [27]. Water solubility and cellular absorption were greatly increased by apigenin nanomixed micelles [28] of apigenin. Apigenin's solid dispersion based on carbon nanopowder increased stability and Apigenin's bioavailability [28]. Nanoliposomes with apigenin within were said to prevent cells from going into myocardial cells in diabetic cardiomyopathy rats [29].

Myricitrin

Myricitrin has been shown to have improved oral bioavailability and therapeutic efficacy by the use of many nanoformulations. It has been discovered that the solid lipid nanocarrier system is an outstanding platform for myricitrin oral administration to treat type 2 diabetes and oxidative stress brought on by diabetes mice under stress [59]. Solid lipid nanoparticles with myricetin were able to release the drug over time derived from the formulation and showed a fantastic therapeutic result in reversing hyperglycemia, apoptosis of the pancreas in vitro, impaired myotube glucose absorption, insulin

resistance, and alive [69]. It was discovered that myricetin nanoparticles were more efficient than metformin at substantially less of a dose [70]. The same group has also claimed that solid lipid nanoparticles with myricetin in them can reduce oxidative damage, inflammation, and fibrosis brought on by hyperglycemia.

Baicalin

A viable strategy to increase baicalin's bioavailability and improve clinical efficacy has been identified as developing nanoscale formulations of baicalin [15,30]. Baicalin-entrapped according to reports, nanoliposomes are a great formulation for oral distribution that exhibits Baicalin now has better oral bioavailability, biodistribution, and stability [31]. Akin to this, baicalin-loaded improvement was seen in nanomicelles made of sodium taurocholate and pluronic P123 copolymer when compared to baicalin, oral bioavailability (> 1.5-fold), absorption, circulation duration, and Baicalin oral administration can thus be accomplished through suspension in rats, which is a promising method [32]. Baicalin's oral bioavailability was found to be improved by several nanoformulations; nonetheless, regarding the therapeutic advantage of baicalin in managing diabetes, there is only one piece of material available presenting baicalin-loaded nanostructured lipid carriers.

luteolin

It has been discovered that creating luteolin nanoformulations improves its oral bioavailability [33,34]. It has been discovered that poly(-caprolactone)-PLGA-nature oil with luteolin assemblybe an appropriate nanocarrier to increase its dispersion in the aqueous medium and bioavailability in oral form [31]. Solid lipid nanoparticles loaded with luteolin have been shown to improve4.8-fold increase in luteolin's solubility, biological half-life, and bioavailability enhanced its medicinaleffectiveness [35]. However, more research needs to be done on how luteolin nanoparticles affect diabetic mice.

Mangiferin

In contrast with existing mangiferin definitions, the making of nanoparticle-based drug conveyance frameworks has been recommended to be an optimal device for upgrading the biopharmaceutical properties and restorative adequacy of mangiferin [5,12]. Self-collected phospholipidic nanomicelles containing mangiferin have been displayed to improve the biopharmaceutical properties of mangiferin [17]. Mangiferin's oral bioavailability and gastrointestinal porousness might be worked on by self-gathered phosholipidic nanomixed micelles frameworks that are co-stacked with vitamin E-TPGS (D-tocopheryl polyethylene glycol 1000 succinate) [5]. To accomplish target selectivity, pepsin obstruction, assurance from the probiotic microscopic organisms in the colon, and supported discharge characteristics, mangiferin-exemplified - lactoglobulin nanoparticles have been created to control mangiferin by means of oral course [26]. Mangiferin nanoparticles may affect diabetes, yet more examination is required.

Asiatic acid

The use of nanotechnology has been proven to be a useful tool for overcoming pharmaceutical restrictions, enhancing compliance, and enhancing asiatic acid's therapeutic efficacy [82]. Asiatic acid oral bioavailability has been reported to be enhanced by solid lipid nanoparticles coated with tromethamine salt. Rats were exposed to (2.5-fold) more asiatic acid when it was free [41]. nanostructured asiatic acid that has been PEGylated Asiatic acid's ability to penetrate and move across lipid carriers was improved in the tiny rats' intestines [26]. It was discovered that the PEG-modified nanoformulation enhanced oral bioavailability the lengthening (by around twofold) of the elimination half-life of asiatic acid [67]. Though, the it is still unknown how asiatic acid nanoparticles may affect diabetes.

Table 1: Limitations of plant-derived antidiabetic compounds in terms of pharmaceutical use

S.No	Compounds	Pharmaceutical limitations	References
1	Curcumin	water solvency ~ 8 mg/L, unfortunate compound security, low vulnerability, unfortunate ingestion, fast digestion, high waste discharge, end half-life ~ 2 h.	74–75
2	Resveratrol	water dissolvability ~ 30 mg/L, fast digestion, quick disposal, low plasma focus, restricted foundational dissemination, oral bioavailability ~ 1-5%, poor physicochemical soundness, fast trans to cis (less dynamic) isomerization.	76-77
3	Naringenin	water dissolvability ~ 9.8 mg/L, low assimilation, fast metabolic change by the hepatic and gastric compounds, oral bioavailability ~ 5%, high gastrointestinal P-gp efflux	78

4	Quercetin	water dissolvability ~ 10 mg/L, poor chemicobiological security, low retention, quick digestion, fast end, unfortunate oral bioavailability ~ 1%.	79
5	Betulin	Low fluid dissolvability, high penetrability, low and variable bioavailability	66-67
6	Crocetin	Water dissolvability ~ 1.2 mg/L, precariousness, quick assimilation, low oral bioavailability.	68
7	Rhein	Low hydrophilicity, watery dissolvability < 1 mg/L, low oral ingestion, quick metabolic debasement, unfortunate oral bioavailability t1/2 ~ 15 min	80
8	Bixin	Unfortunate water solvency, exceptionally unfortunate compound dependability	76
9	Emodin	Water solvency ~ 222 mg/L, poor digestive assimilation, quicker digestion, fast disposal, low bioavailability	77
10	Asiatic Acid	Unfortunate water solvency ~ 158 mg/L (in immersed saline), fast hepatic digestion, unfortunate oral bioavailability (~ 16% in rodents)	73
11	Pelargonidin	Low water dissolvability, unfortunate solidness, fast metabolic corruption, unfortunate bioavailability	79
12	Gallic Acid	Quick gastrointestinal retention, quick foundational digestion, fast disposal, unfortunate oral bioavailability	81
13	Ferulic Acid	Unfortunate water solvency, poor gastrointestinal steadiness, quick digestion, low bioavailability ~ 3%.	82
14	Lycopene	Widely isomerized in the wake of dosing, compound flimsiness, quickly utilized into polar metabolites, fast discharge.	83
15	Lutein	High lipophilicity, unfortunate water dissolvability, unfortunate physic-compound soundness, low oral bioavailability.	84

Table 2: Lists the medicinal plants' names, families, and hypoglycemic properties that have been researched.

S.No	Plant name	Family	Activity	References
1	Brassica juncea	Cruciferae	Hypoglycemic	54
2	Zygophyllum album	Zygophyllaceae	Antidiabetes	55
3	Vitex negundo	Lamiaceae	Antihyperglycemic	56
4	Acacia Arabica	Fabaceae	Antidiabetes	57
5	Psidium guajava	Myrtaceae	Antidiabetes	58
6	Bryophyllum pinnatum	Crassulaceae	STZ rat	59
7	Asteracantha longifolia	Acanthaceae	Diabetic patients	46
8	Bombax ceiba	Bombacaceae	Rats	47
9	Solanum verbascifolium	Solanaceae	Diabetic rabbit	48
10	Spinacea oleracea L	Solanaceae	Rabbit	49
11	Bouvardia ternifolia	Bouvardia ternifolia	Diabetes mice	50
12	Ocimum sanctum	Lamiaceae	Antidiabetes	51
13	Opuntia streptacantha	Cactaceae	Antihyperglycemic	52
14	Albizia odoratissima	Mimoaceae	Antidiabetes	53
15	Cocos nucifera L	Arecaceae	Antidiabetic activity	40
16	Aloe vera Indian Aloe Ghikanvar	Liliaceae	NIDDM patients	41
17	Allium sativum	Liliaceae	Diabetic rabbits	42
18	Anemarrhena asphodeloides	Liliaceae	Diabetic mice	43
19	Allium cepa	Liliaceae	Diabetic rat	44
20	Phyllanthus amarus	Euphorbiaceae	Diabetic patients	45

Nano formulations for the Treatment of Diabetes

Approaches based on nanotechnology provide better therapeutic control of diabetes mellitus with reduced risk of acute and long-term consequences [1]. Countless Nano formulation for the management of diabetic mellitus, many structures have been created [15]. Formulations based on nanocarriers guarantee effective drug delivery to the target site with the pattern of release that is intended [1,12]. Additionally, Nano formulation permits the delivery of medications via different routes [16, 17]. When nanocarriers are created with the right ligands, they become more focused and can improve the stability and systemic availability of medications. The creation of nano carriers also cut back on the drug's dosage and administration schedule. Manufactured Nanoformulation are the last can lower the chance

of toxic symptoms [1, 18]. Therefore, appropriately created Nano formulations of hypoglycemic medications may provide enhanced.

Table 3: Advantages and limitations for different types of nanoparticles

Types of nanoparticles	Advantages	Limitations
Polymeric nanoparticles	Degrade into biologically acceptable compounds by hydrolysis; lesser cytotoxicity; higher target-specificity; high level of insulin entrapment and ability to preserve insulin structure and biological activity; bypassing of the enzymatic degradation in the stomach	Mucoadhesive polymeric nanoparticles may adhere nonspecifically to the surfaces they are not intended to (gastric mucosa, gut content) or remain trapped within the mucus
Liposomes	Biodegradable, non-toxic and non-immunogenic	Drug loading capacity remains inconclusive; captured by the human body's defense system (reticuloendothelial system (RES)); posttreatment accumulation in skin and eyes
Gold nanoparticles	Long term stability in terms of aggregation and good insulin loading; higher uptake of insulin across oral and nasal mucosa; improved pharmacodynamics activity of insulin	Widespread distribution in organs like liver, lung, spleen, kidney, brain, heart, stomach and joints
Ceramic nanoparticles	Easy preparative processes; high biocompatibility; ultralow size (less than 50 nm); good dimensional stability; protect the doped drug molecules against denaturation caused by changes in external pH and temperature; can be manufactured with desired size, shape and porosity; do not undergo swelling or porosity changes	Poor permeability across the mucosal membrane and rapid mucociliary clearance mechanism of nonmucoadhesive formulations for nasally administered insulin



Figure 6: Different types of nanoparticles pictorial view



Figure 7: Nanoparticles pictorial view.

4. Conclusion

Long-term treatment is necessary for chronic metabolic syndrome conditions like diabetes. Thus, the most important factor to consider when formulating Pharmacotherapeutics drugs for the treatment of diabetes is patient compliance. Oral formulation is typically chosen in this context. Plant-derived a good opportunity to lessen diabetes and its problems is provided by antidiabetic chemicals. However, phytochemicals' subpar biopharmaceutical and pharmacokinetic characteristics essentially restrict their use their ability to treat illness. Various plant-derived antidiabetic Nano formulations have been developed over the year's molecules such nanoemulsions, nanocarrier-assembled nanoparticles, and polymeric nanoparticles solid dispersions, nanoliposomes, nanostructured lipid carriers, nanomicelles, and solid lipid nanoparticles moreover, nanocrystals have been created. For the oral transport of the majority of plant-based chemicals, such as curcumin, resveratrol, quercetin, silymarin, pelargonidin, thromboquinone, ferulic acid, crocetin, and -oryzanol, PLGA has been proposed as a possible nanocarrier [73, 74, 79, 80, 82, 83]. Although it has been asserted that the oral bioavailability and anti-diabetic effectiveness of the aforementioned plant-derived small molecules are improved by PLGA-loaded nanoformulation, PLGA is highly susceptible to the hydrolytic destruction in gastrointestinal environments. In this context, the PLA/PGA ratio in PLGA is crucial, and it's important to precisely address how different PLGA grades affect nanocarrier performance. Chitosan has been recognized as a suitable nanocarrier for the oral delivery of curcumin, naringenin, quercetin, gymnemic acid, rosmarinic acid, scutellarin, silybin, and other anti-diabetic phytochemicals [20,22,24,25,27,28]. This improves compliance and pharmacokinetic properties. Currently, the anti-diabetic properties of more than 400 plants have received clinical validation properties. These plants have been progressively gaining popularity as allopathic drug substitutes. Numerous investigations on nanocarrier's formulations for anti-diabetic drugs have been done to get around the drawbacks of plant-based diets, use bioactive substances and plant extracts products with weak permeability, low bioavailability, and low solubility. The top metallic nanoparticles have demonstrated abilities to counteract the effects of antidiabetic medications and liposomes because of their adaptability and wide range of applications. The success has proven successful in using these plant-based Nano formulations to treat hyperglycemia-related disorders confirmed by tests both in vivo and in vitro. Consequently, nanocarriers for herbal usage of anti-diabetic medications as complementary therapies for diabetes mellitus are highly promising.

Conflicts of Interest: The authors say they have no competing interests.

References:

1. Kesharwani, P.; Gorain, B.; Low, S.Y.; Tan, S.A.; Ling, E.C.S.; Lim, Y.K.; Chin, C.M.; Lee, P.Y.; Lee, C.M.; Ooi, C.H.; et al. Nanotechnology based approaches for anti-diabetic drugs delivery. Diabetes Res. Clin. Pract. 2018, 136, 52–77. [CrossRef] [PubMed]

2. Patra, J.K.; Das, G.; Fraceto, L.F.; Campos, E.V.R.; Rodriguez-Torres, M.D.P.; Acosta-Torres, L.S.; Diaz-Torres, L.A.; Grillo, R.; Swamy, M.K.; Sharma, S.; et al. Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnol. 2018, 16, 71. [CrossRef] [PubMed]
3. Aryaeian, N.; Sedehi, S.K.; Arablou, T. Polyphenols and their effects on diabetes management: A review. Med. J. Islam. Repub. Iran. 2017, 31, 134. [CrossRef]
4. Brglez Mojzer, E.; Knez Hrnˇciˇc, M.; Škerget, M.; Knez, Ž.; Bren, U. Polyphenols: Extraction methods, antioxidative action, bioavailability and anticarcinogenic effects. Molecules 2016, 21, 901. [CrossRef] [PubMed]
5. Khurana, R.K.; Gaspar, B.L.; Welsby, G.; Katare, O.P.; Singh, K.K.; Singh, B. Improving the biopharmaceutical attributes of mangiferin using vitamin E-TPGS co-loaded self-assembled phosholipidic nano-mixed micellar systems. Drug Deliv. Transl. Res. 2018, 8, 617–632. [CrossRef]
6. Sharma, M.; Sharma, R.; Jain, D.K. Nanotechnology based approaches for enhancing oral bioavailability of poorly water-soluble antihypertensive drugs. Scientifica 2016, 2016, 8525679. [CrossRef]
7. Hu, F.B. Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care 2011, 34, 1249–1257. [CrossRef]
8. Li, Y.; Zhang, J.; Gu, J.; Chen, S.; Wang, C.; Jia, W. Biosynthesis of polyphenol-stabilised nanoparticles and assessment of anti-diabetic activity. J. Photochem. Photobiol. B 2017, 169, 96–100. [CrossRef]
9. Bhattacharjee, N.; Dua, T.K.; Khanra, R.; Joardar, S.; Nandy, A.; Saha, A.; De Feo, V.; Dewanjee, S. Protocatechuic acid, a phenolic from Sansevieria roxburghiana leaves, suppresses diabetic cardiomyopathy via stimulating glucose metabolism, ameliorating oxidative stress, and inhibiting inflammation. Front. Pharmacol. 2017, 8, 251. [CrossRef]
10. Gothai, S.; Ganesan, P.; Park, S.Y.; Fakurazi, S.; Choi, D.K.; Arulselvan, P. Natural phyto-bioactive compounds for the treatment of type 2 diabetes: Inflammation as a target. Nutrients 2016, 8, 461. [CrossRef]
11. Qaseem, A.; Humphrey, L.L.; Sweet, D.E.; Starkey, M.; Shekelle, P. Oral pharmacologic treatment of type 2 diabetes mellitus: A clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 2012, 156, 218–231. [CrossRef] [PubMed]
12. Dewanjee, S.; Das, S.; Das, A.K.; Bhattacharjee, N.; Dihingia, A.; Dua, T.K.; Kalita, J.; Manna, P. Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. Eur. J. Pharmacol. 2018, 833, 472–523. [CrossRef] [PubMed]
13. Dewanjee, S.; Bhattacharjee, N. MicroRNA: A new generation therapeutic target in diabetic nephropathy. Biochem. Pharmacol. 2018, 155, 32–47. [CrossRef] [PubMed]
14. Bhattacharjee, N.; Barma, S.; Konwar, N.; Dewanjee, S.; Manna, P. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update. Eur. J. Pharmacol. 2016, 791, 8–24. [CrossRef] [PubMed]
15. Khanra, R.; Bhattacharjee, N.; Dua, T.K.; Nandy, A.; Saha, A.; Kalita, J.; Manna, P.; Dewanjee, S. Taraxerol, a pentacyclic triterpenoid, from Abroma augusta leaf attenuates diabetic nephropathy in type 2 diabetic rats. Biomed. Pharmacother. 2017, 94, 726–741. [CrossRef]
16. Xavier, G.D.S. The cells of the islets of langerhans. J. Clin. Med. 2018, 7, 54. [CrossRef]
17. Berenson, D.F.; Weiss, A.R.; Wan, Z.L.; Weiss, M.A. Insulin analogs for the treatment of diabetes mellitus: Therapeutic applications of protein engineering. Ann. N. Y. Acad. Sci. 2011, 1243, E40–E54. [CrossRef]
18. Tadera, K.; Minami, Y.; Takamatsu, K.; Matsuoka, T. Inhibition of alpha-glucosidase and alpha-amylase by flavonoids. J. Nutr. Sci. Vitaminol. (Tokyo) 2006, 52, 149–153. [CrossRef]
19. Kamiyama, O.; Sanae, F.; Ikeda, K.; Higashi, Y.; Minami, Y.; Asano, N.; Adachi, I.; Kato, A. In vitro inhibition of a-glucosidases and glycogen phosphorylase by catechin gallates in green tea. Food Chem. 2010, 122, 1061–1066. [CrossRef]
20. Arumugam, B.; Palanisamy, U.D.; Chua, K.H.; Kuppusamy, U.R. Potential antihyperglycaemic effect of myricetin derivatives from Syzygium malaccense. J. Funct. Foods 2016, 22, 325–336. [CrossRef]
21. Rasouli, H.; Hosseini-Ghazvini, S.M.; Adibi, H.; Khodarahmi, R. Differential α-amylase/α-glucosidase inhibitory activities of plant-derived phenolic compounds: A virtual screening perspective for the treatment of obesity and diabetes. Food Funct. 2017, 8, 1942–1954. [CrossRef] [PubMed]
22. Ngo, Y.L.; Lau, C.H.; Chua, L.S. Review on rosmarinic acid extraction, fractionation and its anti-diabetic potential. Food Chem. Toxicol. 2018, 121, 687–700. [CrossRef] [PubMed]
23. Li, K.; Yao, F.; Xue, Q.; Fan, H.; Yang, L.; Li, X.; Sun, L.; Liu, Y. Inhibitory effects against α-glucosidase and α-amylase of the flavonoids-rich extract from Scutellaria baicalensis shoots and interpretation of structure-activity relationship of its eight flavonoids by a refined assign-score method. Chem. Cent. J. 2018, 12, 82. [CrossRef] [PubMed]
24. Thadhani, V.M. Resveratrol in Management of Diabetes and Obesity: Clinical Applications, Bioavailability, and Nanotherapy. In Resveratrol-Adding Life to Years, Not Adding Years to Life; IntechOpen: Rijeka, Croatia, 2019; pp. 139–156.
25. Oh, Y.S. Plant-derived compounds targeting pancreatic beta cells for the treatment of diabetes. Evid. Based Complement. Altern. Med. 2015, 2015, 629863. [CrossRef]
26. Rouse, M.; Younès, A.; Egan, J.M. Resveratrol and curcumin enhance pancreatic β-cell function by inhibiting phosphodiesterase activity. J. Endocrinol. 2014, 223, 107–117. [CrossRef]

27. Wu, L.; Zhou, L.; Lu, Y.; Zhang, J.; Jian, F.; Liu, Y.; Li, F.; Li, W.; Wang, X.; Li, G. Activation of SIRT1 protects pancreatic β-cells against palmitate-induced dysfunction. Biochim. Biophys. Acta 2012, 1822, 1815–1825. [CrossRef]
28. Suman, R.K.; Mohanty, I.R.; Maheshwari, U.; Borde, M.K.; Deshmukh, Y.A. Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats. Diabetes Metab. Syndr. Obes. 2016, 9, 261–272. [CrossRef]
29. Shenoy, R.S.; Prashanth, K.V.H.; Manonmani, H.K. In Vitro antidiabetic effects of isolated triterpene glycoside fraction from gymnema sylvestre. Evid. Based Complement. Altern. Med. 2018, 2018, 7154702. [CrossRef]
30. Jeppesen, P.B.; Gregersen, S.; Poulsen, C.R.; Hermansen, K. Stevioside acts directly on pancreatic beta cells to secrete insulin: Actions independent of cyclic adenosine monophosphate and adenosine triphosphate-sensitive K+-channel activity. Metabolism 2000, 49, 208–214. [CrossRef]
31. Philippaert, K.; Pironet, A.; Mesuere, M.; Sones, W.; Vermeiren, L.; Kerselaers, S.; Pinto, S.; Segal, A.; Antoine, N.; Gysemans, C.; et al. Steviol glycosides enhance pancreatic beta-cell function and taste sensation by potentiation of TRPM5 channel activity. Nat. Commun. 2017, 8, 14733. [CrossRef]
32. Liu, J.; He, T.; Lu, Q.; Shang, J.; Sun, H.; Zhang, L. Asiatic acid preserves beta cell mass and mitigates hyperglycaemia in streptozocin-induced diabetic rats. Diabetes Metab. Res. Rev. 2010, 26, 448–454. [CrossRef] [PubMed]
33. Ghorbani, A.; Rashidi, R.; Shafiee-Nick, R. Flavonoids for preserving pancreatic beta cell survival and function: A mechanistic review. Biomed. Pharmacother. 2019, 111, 947–957. [CrossRef] [PubMed]
34. Den Hartogh, D.J.; Tsiani, E. Antidiabetic properties of naringenin: A citrus fruit polyphenol. Biomolecules 2019, 9, 99. [CrossRef] [PubMed]
35. Soto, C.; Raya, L.; Pérez, J.; González, I.; Pérez, S. Silymarin induces expression of pancreatic Nkx6.1 transcription factor and β-cells neogenesis in a pancreatectomy model. Molecules 2014, 19, 4654–4668. [CrossRef]
36. Sameermahmood, Z.; Raji, L.; Saravanan, T.; Vaidya, A.; Mohan, V.; Balasubramanyam, M. Gallic acid protects RINm5F beta-cells from glucolipotoxicity by its antiapoptotic and insulin-secretagogue actions. Phytother. Res. 2010, 24, S83–S94. [CrossRef]
37. Boucher, J.; Kleinridders, A.; Kahn, C.R. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb. Perspect. Biol. 2014, 6, a009191. [CrossRef]
38. Puigserver, P.; Rhee, J.; Donovan, J.; Walkey, C.J.; Yoon, J.C.; Oriente, F.; Kitamura, Y.; Altomonte, J.; Dong, H.; Accili, D.; et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003, 423, 550–555. [CrossRef]
39. Eid, S.; Boutary, S.; Braych, K.; Sabra, R.; Massaad, C.; Hamdy, A.; Rashid, A.; Moodad, S.; Block, K.; Gorin, Y.; et al. mTORC2 signaling regulates Nox4-induced podocyte depletion in diabetes. Antioxid. Redox Signal. 2016, 25, 703–719. [CrossRef]
40. Sindurani JA, Rajamohan T. Effects of different levels of coconut fiber on blood glucose, serum insulin and minerals in rats. Indian J Physiol Pharmacol 2000; 44: 97-100.
41. Alawadi, F.M., Katar, M.A. and Gumaa, K.A. (1985) On the mechanism ohypoglycemic effect of a plant extract. Dibetologia 28, 432-438.
42. Zhang, D.W.; Fu, M.; Gao, S.H.; Liu, J.L. Curcumin and diabetes: A systematic review. Evid. Based Complement. Altern. Med. 2013, 2013, 636053. [CrossRef] [PubMed]
43. Al-Ishaq, R.K.; Abotaleb, M.; Kubatka, P.; Kajo, K.; Büsselberg, D. Flavonoids and their anti-diabetic effects: Cellular mechanisms and effects to improve blood sugar levels. Biomolecules 2019, 9, 430. [CrossRef] [PubMed]
44. Kawser Hossain, M.; Abdal Dayem, A.; Han, J.; Yin, Y.; Kim, K.; Kumar Saha, S.; Yang, G.M.; Choi, H.Y.; Cho, S.G. Molecular mechanisms of the anti-obesity and anti-diabetic properties of flavonoids. Int. J. Mol. Sci. 2016, 17, 569. [CrossRef] [PubMed]
45. Yin, J.; Ye, J.; Jia, W. Effects and mechanisms of berberine in diabetes treatment. Acta Pharm. Sin. 2012, 2, 327–334. [CrossRef]
46. Rizzo, B.; Zambonin, L.; Angeloni, C.; Leoncini, E.; Dalla Sega, F.V.; Prata, C.; Fiorentini, D.; Hrelia, S. Steviol glycosides modulate glucose transport in different cell types. Oxid. Med. Cell. Longev. 2013, 2013, 348169. [CrossRef] [PubMed]
47. Ramachandran, V.; Saravanan, R. Glucose uptake through translocation and activation of GLUT4 in PI3K/Akt signaling pathway by asiatic acid in diabetic rats. Hum. Exp. Toxicol. 2015, 34, 884–893. [CrossRef]
48. Sil, R.; Ray, D.; Chakraborti, A.S. Glycyrrhizin ameliorates insulin resistance, hyperglycaemia, dyslipidemia and oxidative stress in fructose-induced metabolic syndrome-X in rat model. Indian J. Exp. Biol. 2013, 51, 129–138.
49. Variya, B.C.; Bakrania, A.K.; Patel, S.S. Antidiabetic potential of gallic acid from Emblica officinalis: Improved glucose transporters and insulin sensitivity through PPAR-γ and Akt signaling. Phytomedicine 2019, 152906. [CrossRef]
50. Badr, G.; Mahmoud, M.H.; Farhat, K.; Waly, H.; Al-Abdin, O.Z.; Rabah, D.M. Maternal supplementation of diabetic mice with thymoquinone protects their offspring from abnormal obesity and diabetes by modulating their lipid profile and free radical production and restoring lymphocyte proliferation via PI3K/AKT signaling. Lipids Health Dis. 2013, 12, 37. [CrossRef]

51. Jay, M.A.; Ren, J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr. Diabetes Rev. 2007, 3, 33–39. [CrossRef]
52. Pan, Y.; Zhao, D.; Yu, N.; An, T.; Miao, J.; Mo, F.; Gu, Y.; Zhang, D.; Gao, S.; Jiang, G. Curcumin improves glycolipid metabolism through regulating peroxisome proliferator activated receptor γ signalling pathway in high-fat diet-induced obese mice and 3T3-L1 adipocytes. R. Soc. Open Sci. 2017, 4, 170917. [CrossRef] [PubMed]
53. Zhang, Q.; Xiao, X.; Feng, K.; Wang, T.; Li, W.; Yuan, T.; Sun, X.; Sun, Q.; Xiang, H.; Wang, H. Berberine moderates glucose and lipid metabolism through multipathway mechanism. Evid. Based Complement. Altern. Med. 2011, 2011, 924851. [CrossRef] [PubMed
54. Eu, C.H.; Lim, W.Y.; Ton, S.H.; bin Abdul Kadir, K. Glycyrrhizic acid improved lipoprotein lipase expression, insulin sensitivity, serum lipid and lipid deposition in high-fat diet-induced obese rats. Lipids Health Dis. 2010, 9, 81. [CrossRef] [PubMed]
55. Lu, K.; Han, M.; Ting, H.L.; Liu, Z.; Zhang, D. Scutellarin from Scutellaria baicalensis suppresses adipogenesis by upregulating PPARα in 3T3-L1 cells. J. Nat. Prod. 2013, 76, 672–678. [CrossRef] [PubMed]
56. Cho, K.W.; Kim, Y.O.; Andrade, J.E.; Burgess, J.R.; Kim, Y.C. Dietary naringenin increases hepatic peroxisome proliferators-activated receptor α protein expression and decreases plasma triglyceride and adiposity in rats. Eur. J. Nutr. 2011, 50, 81–88. [CrossRef] [PubMed]
57. Chang, C.J.; Tzeng, T.F.; Liou, S.S.; Chang, Y.S.; Liu, I.M. Myricetin increases hepatic peroxisome proliferator-activated receptor α protein expression and decreases plasma lipids and adiposity in rats. Evid. Based Complement. Altern. Med. 2012, 2012, 787152. [CrossRef]
58. Wang, M.I.; Xiao, F.L.; Mao, Y.J.; Ying, L.L.; Zhou, B.; Li, Y. Quercetin decreases the triglyceride content through the PPAR signalling pathway in primary hepatocytes of broiler chickens. Biotechnol. Biotechnol. Equip. 2019, 33, 1000–1010. [CrossRef]
59. Fomenko, E.V.; Chi, Y. Mangiferin modulation of metabolism and metabolic syndrome. Biofactors 2016, 42, 492–503. [CrossRef]60. Naowaboot, J.; Piyabhan, P.; Munkong, N.; Parklak, W.; Pannangpetch, P. Ferulic acid improves lipid and glucose homeostasis in high-fat diet-induced obese mice. Clin. Exp. Pharmacol. Physiol. 2016, 43, 242–250. [CrossRef]
60. Naowaboot, J.; Piyabhan, P.; Munkong, N.; Parklak, W.; Pannangpetch, P. Ferulic acid improves lipid and glucose homeostasis in high-fat diet-induced obese mice. Clin. Exp. Pharmacol. Physiol. 2016, 43, 242–250. [CrossRef]
61. Goto, T.; Takahashi, N.; Kato, S.; Kim, Y.I.; Kusudo, T.; Taimatsu, A.; Egawa, K.; Kang, M.S.; Hiramatsu, T.; Sakamoto, T.; et al. Bixin activates PPARα and improves obesity-induced abnormalities of carbohydrate and lipid metabolism in mice. J. Agric. Food Chem. 2012, 60, 11952–11958. [CrossRef]
62. Gu, M.; Zhao, P.; Huang, J.; Zhao, Y.; Wang, Y.; Li, Y.; Li, Y.; Fan, S.; Ma, Y.M.; Tong, Q.; et al. Silymarin ameliorates metabolic dysfunction associated with diet-induced obesity via activation of farnesyl X receptor. Front. Pharmacol. 2016, 7, 345. [CrossRef] [PubMed]
63. Chen, Y.; Li, J.; Yan, Y.; Shen, X. Diabetic macular morphology changes may occur in the early stage of diabetes. BMC Ophthalmol. 2016, 16, 12. [CrossRef]
64. Xu, G.; Sun, W.; Guo, X.; Wu, L.; Hou, Y.; Ma, X.; Qin, L.; Gao, M.; Liu, T. Asiatic acid promotes liver fatty acid metabolism in diabetic models. Int. J. Clin. Exp. Med. 2018, 11, 11837–11845.
65. Li, Y.; Sun, M.; Liu, Y.; Liang, J.; Wang, T.; Zhang, Z. Gymnemic acid alleviates type 2 diabetes mellitus and suppresses endoplasmic reticulum stress in vivo and in vitro. J. Agric. Food Chem. 2019, 67, 3662–3669. [CrossRef] [PubMed]
66. Domínguez-Avila, J.A.; González-Aguilar, G.A.; Alvarez-Parrilla, E.; de la Rosa, L.A. Modulation of PPAR expression and activity in response to polyphenolic compounds in high fat diets. Int. J. Mol. Sci. 2016, 17, 1002. [CrossRef] [PubMed]
67. Floyd, Z.E.; Wang, Z.Q.; Kilroy, G.; Cefalu, W.T. Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol. Metabolism 2008, 57, S32–S38. [CrossRef]
68. Bing, S.; Haoqiang, Z.; Chunyu, M.; Yali, Y.; Jing, W.; Yumeng, G.; Hongwei, Z.; Xuezheng, L. The effects of emodin on insulin resistance in KKAy mice with diabetes mellitus. Pharmacogn. Mag. 2018, 14, 344–350.
69. Pang, B.; Zhao, L.H.; Zhou, Q.; Zhao, T.Y.; Wang, H.; Gu, C.J.; Tong, X.L. Application of berberine on treating type 2 diabetes mellitus. Int. J. Endocrinol. 2015, 2015, 905749. [CrossRef]
70. Chae, B.S. Protective effect of baicalin on the TNF-α-mediated development of insulin resistance in differentiated 3T3-L1 cells. Nat. Prod. Sci. 2013, 19, 316–323. 71. Cho, S.Y.; Park, P.J.; Shin, H.J.; Kim, Y.K.; Shin, D.W.; Shin, E.S.; Lee, H.H.; Lee, B.G.; Baik, J.H.; Lee, T.R. (-)-Catechin suppresses expression of Kruppel-like factor 7 and increases expression and secretion of adiponectin protein in 3T3-L1 cells. Am. J. Physiol. Endocrinol. Metab. 2007, 292, E1166–E1172. [CrossRef]
72. Dodda, D.; Ciddi, V. Plants used in the management of diabetic complications. Indian J. Pharm Sci. 2014, 76, 97–106. [PubMed]
73. Parsamanesh, N.; Moossavi, M.; Bahrami, A.; Butler, A.E.; Sahebkar, A. Therapeutic potential of curcumin in diabetic complications. Pharmacol. Res. 2018, 136, 181–193. [CrossRef] [PubMed]
74. Oyenihi, O.R.; Oyenihi, A.B.; Adeyanju, A.A.; Oguntibeju, O.O. Antidiabetic effects of resveratrol: The way forward in its clinical utility. J. Diabetes Res. 2016, 2016, 9737483. [CrossRef] [PubMed

75. Suresh, K.; Nangia, A. Curcumin: Pharmaceutical solids as a platform to improve solubility and bioavailability. CrystEngComm 2018, 24, 3277–3296. [CrossRef]
76. Ernest, U.; Chen, H.Y.; Xu, M.J.; Taghipour, Y.; Asad, M.; Rahimi, R.; Murtaza, G. Anti-cancerous potential of polyphenol-loaded polymeric nanotherapeutics. Molecules 2018, 23, 2787. [CrossRef] [PubMed]
77. Metzler, M.; Pfeiffer, E.; Schulz, S.I.; Dempe, J.S. Curcumin uptake and metabolism. Biofactors 2013, 39, 14–20. [CrossRef] [PubMed]
78. Peñalva, R.; Morales, J.; González-Navarro, C.J.; Larrañeta, E.; Quincoces, G.; Peñuelas, I.; Irache, J.M. Increased oral bioavailability of resveratrol by its encapsulation in casein nanoparticles. Int. J. Mol. Sci. 2018, 19, 2816. [CrossRef] [PubMed]
79. Chimento, A.; De Amicis, F.; Sirianni, R.; Sinicropi, M.S.; Puoci, F.; Casaburi, I.; Saturnino, C.; Pezzi, V. Progress to improve oral bioavailability and beneficial effects of resveratrol. Int. J. Mol. Sci. 2019, 20, 1381. [CrossRef]
80. Mohamadi, N.; Sharififar, F.; Pournamdari, M.; Ansari, M. A review on biosynthesis, analytical techniques, and pharmacological activities of trigonelline as a plant alkaloid. J. Diet. Suppl. 2018, 15, 207–222. [CrossRef]
81. Zhang, Y.; Fei, F.; Zhen, L.; Zhu, X.; Wang, J.; Li, S.; Geng, J.; Sun, R.; Yu, X.; Chen, T.; et al. Sensitive analysis and simultaneous assessment of pharmacokinetic properties of crocin and crocetin after oral administration in rats. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2017, 1044–1045, 1–7. [CrossRef]
82. Yang, X. Design and optimization of crocetin loaded PLGA nanoparticles against diabetic nephropathy via suppression of inflammatory biomarkers: A formulation approach to preclinical study. Drug Deliv. 2019, 26, 849–859. [CrossRef]
83. Feng, H.; Zhu, Y.; Fu, Z.; Li, D. Preparation, characterization, and in vivo study of rhein solid lipid nanoparticles for oral delivery. Chem. Biol. Drug Des. 2017, 90, 867–872. [CrossRef]
84. Gouda, W.; Hafiz, N.A.; Mageed, L.; Alazzouni, A.S.; Khalil, W.K.; Afify, M.; Abdelmaksoud, M.D. Effects of nano-curcumin on gene expression of insulin and insulin receptor. Bull. Natl. Res. Cent. 2019, 43, 128. [CrossRef]